

ASX Announcement

16 March 2021

Regeneus to be granted new Progenza™ patent to treat pain in Europe

Highlights

- European Patent Office has issued a Notice of Intention to grant a new key patent for its lead stem cell technology platform Progenza™
- The patent once granted will provide commercial rights in Europe until 2032
- The patent covers the treatment of pain using Progenza™

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today announced that the European Patent Office has issued a Notice of Intention to grant a new key patent for Regeneus' lead stem cell technology platform Progenza™.

Once granted, the patent gives Regeneus protection for Progenza™ for the treatment of pain in Europe through to 2032. This expands Progenza™'s IP protection in Europe beyond the previously granted patent for the treatment of inflammatory conditions.

Regeneus CEO Karolis Rosickas said, "It is positive to see our patents being allowed and granted across the major European, US and Japanese markets.

This patent will help facilitate our discussions with commercial partners for licensing Progenza™ for the \$85.5 billionⁱ global pain market".

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications

T: 02 9237 2805

E: WE-AURegeneus@we-worldwide.com

ⁱ Allied Market Research, *Pain Management Drugs Market by Drug Class, (NSAIDs, Anesthetics, Anticonvulsant, Anti-Migraine Drug, Antidepressant Drugs, Opioids, and Non-Narcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, and Fibromyalgia): Global Opportunity Analysis and Industry Forecast, 2019–2027 (2020)*